Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Next Previous
Trial Profile

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 15 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 25 Jan 2022 According to a Neurophth Therapeutics media release, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for NR082 for the treatment of Leber's hereditary optic neuropathy (LHON) associated with mtND4 mutation, based on compelling IND-enabling data and clinical data of 186 subjects from three investigator-initiated trials (IITs).
  • 24 Sep 2020 According to a Neurophth Therapeutics media release,at the 23rd online annual meeting of the American Society for Gene and Cell Therapy (ASGCT) and the online annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Neurophth presented (in May 2020) the two clinical research data (NCT01267422 and NCT03153293) on the treatment of LHON with NR082 (NFS-01 project of rAAV2-ND4).
  • 24 Sep 2020 Results presented in a Neurophth Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top